SciSparc Ltd (SPRC)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

SciSparc: Subsidiary NeuroThera Labs Completed Acquisition of CliniQuantum

TEL AVIV, Israel, June 04, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

SciSparc: Subsidiary NeuroThera Labs Received Conditional Regulatory Approval for Acquisition of CliniQuantum

TEL AVIV, Israel, May 28, 2026 (GLOBE NEWSWIRE) --  SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”...

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Form 3 - Initial statement of beneficial ownership of securities

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

SciSparc: NeuroThera Labs- Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy

TEL AVIV, Israel, March 16, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”...

Clearmind Medicine Announces Hong Kong Patent Filing for Depression Therapy

Innovative non-hallucinogenic approach combines MEAI with Palmitoylethanolamide to tackle major depressive...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

SciSparc: NeuroThera Labs Announces Publication of International Patent in Collaboration with Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease

TEL AVIV, Israel, March 12, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”...